Disease or Syndrome
Patient Dies from Thrombotic Stroke in Pfizer’s Hympavzi Hemophilia Trial After Minor Surgery
Pfizer; Hympavzi; marstacimab; hemophilia; thrombotic stroke; patient death; clinical trial
Neurocrine’s VMAT2 Inhibitor Valbenazine Fails in Phase 3 Trial for Dyskinetic Cerebral Palsy
Neurocrine; valbenazine; VMAT2 inhibitor; dyskinetic cerebral palsy; KINECT-DCP; Phase 3 trial; chorea
Novo Nordisk Wins FDA Approval for First Oral GLP-1 Wegovy Pill in Obesity Treatment
Novo Nordisk; Wegovy pill; FDA approval; oral semaglutide; obesity treatment; GLP-1
Gilead’s $35M Herpes Deal with Assembly Biosciences and Recent FDA Approvals
Gilead; Assembly Biosciences; herpes; HSV; ABI-1179; ABI-5366; FDA; Boehringer; Roche
FDA Approves Novo Nordisk’s Wegovy Pill as First Oral GLP-1 for Weight Management
Novo Nordisk; Wegovy pill; FDA approval; obesity treatment; oral semaglutide
Shionogi Announces $2.5 Billion Acquisition of ALS Drug Radicava from Tanabe Pharma
Shionogi; Tanabe Pharma; Radicava; ALS; acquisition; $2.5B; rare disease
Spotlight On: Five Key FDA Approvals of 2025
FDA approvals; 2025; orphan drugs; novel therapies; rare diseases
Brainomix AI Reveals Hidden Efficacy of ARG-007 in Severe Stroke Patients
Brainomix; AI; stroke trial; ARG-007; neuroprotective; Argenica Therapeutics; Brainomix 360 Stroke
Breakthrough Real-World Evidence Powering Blood Cancer Research in 2025
RWE; blood cancer; real-world evidence; ASH 2025; SOHO 2025; hematologic care
FDA Approves Cytokinetics’ Myqorzo for Obstructive Hypertrophic Cardiomyopathy, Positioning It Against BMS’s Camzyos
FDA approval; Cytokinetics; Myqorzo; aficamten; obstructive hypertrophic cardiomyopathy; Bristol Myers Squibb; Camzyos